The University of Sheffield announces approval of the first human trial testing regenerative cell therapy to treat sensorineural hearing loss, offering hope for restoring hearing function.
The government has unveiled a transformative initiative that will empower millions of NHS patients to find and join clinical trials via the NIHR’s “Be Part of Research” portal within the NHS App.
New results from a clinical trial reveal that a single dose of psilocybin can provide sustained reductions in depression and anxiety in individuals with cancer suffering from major depressive disorder.
Having a pet dog may lower the risk of eczema in children who are genetically prone to the condition, shedding light on how environmental factors may influence genetic risks.
A groundbreaking study from the Paul Scherrer Institute (PSI) in collaboration with Inselspital–Bern University Hospital has unveiled a promising new therapy for lymphoma using the radioactive isotope terbium-161.
A new study reveals that adults diagnosed with type 1 diabetes face a heightened risk of cardiovascular disease and death, with no better prognosis than those diagnosed in childhood.
A major clinical trial has found that low-dose interleukin-2 (IL2LD) is safe and may significantly extend survival in people with motor neurone disease (ALS).
Professor David Sebag-Montefiore outlines the profound impact of radiotherapy research. Through global trials and personalised approaches, innovation advances cancer care. Collaborative efforts ensure patient-centred treatments, paving the way for smarter, kinder therapies and a future of precision oncology.
A new treatment, Sotatercept, for pulmonary arterial hypertension (PAH) has recently been approved by the Medicines and Healthcare Products Regulatory Agency (MHRA).
Researchers at the Perelman School of Medicine at the University of Pennsylvania have reported improvements in vision among patients with a rare inherited condition, following gene therapy.
An HIV vaccine candidate developed at the Duke Human Vaccine Institute has demonstrated the ability to trigger low levels of a rare type of neutralising antibodies (bnAbs) in a small group of participants.
£2.4 million has been funded to trials evaluating the clinical mechanisms of ADHD, with consideration to its progression with depression, parental impact, and ADHD in women.
With a particular focus on South Korea, Open Access Government explores the changing perceptions around animal welfare and some of the policies introduced to support this.
An experimental Alzheimer's drug called donanemab, developed by Eli Lilly, has demonstrated a slowdown in progression of disease at early stages, according to trial data.
Chronic liver diseases can have a detrimental impact on physical and mental health; we explore the underlying causes, symptoms, and treatment for primary biliary cholangitis.
